Not MSI-High
Not MSI-High status indicates proficient mismatch repair. This classification may influence eligibility for certain immunotherapies.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where Not MSI-High is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Endometrial Carcinoma (EC) Solid Tumor · Endometrium |
|
Approvals defined at the solid tumor level where Not MSI-High is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report Not MSI-High as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports Not MSI-High as part of its biomarker panel.